Prosp ective measurement of glomerular filtration rate and effective renal plasma flow during treatment of malignant essential hypertension

R. R. GHOSE
F.R.C.P.

Singleton Hospital, Sketty, Swansea SA2 8QA

Summary
A longitudinal study of sequential measurement of glomerular filtration rate and effective renal plasma flow was conducted over a 5-year period of antihypertensive drug treatment, in four adult patients admitted to hospital with previously untreated malignant essential hypertension. Treatment produced a substantial and sustained lowering of systemic arterial blood pressure, compared with grossly elevated pretreatment levels. Nevertheless, glomerular filtration rate and effective renal plasma flow remained relatively stable in all four patients, at roughly the same level at which they were admitted. It was concluded that effective therapy for hypertension may not necessarily reverse the vascular changes of arteriolar fibrinoid necrosis, which characterize malignant essential hypertension. Permanent damage to the renal arterioles, and the territory of kidney supplied by these vessels, may be a feature of this condition.

KEY WORDS: glomerular filtration rate, effective renal plasma flow, malignant essential hypertension.

Introduction
There are few prospective studies of renal function in patients who present with malignant essential hypertension (MHT). In a long-term study of 24 patients with MHT it was apparent that the extent of initial renal damage, and the quality of blood pressure (BP) control, were of paramount importance. In 17 patients with initial mean serum creatinine concentration of 169 ± 19 μmol/l, glomerular filtration rate (GFR) increased from 51 ± 7 to 62 ± 6 ml/min. BP control was satisfactory in this group, whereas in seven patients, with initial mean serum creatinine concentrations of 448 ± 105 μmol/l, there was rapid deterioration into end-stage renal failure and BP control was poor (Herlitz, Gudbransson and Hansson, 1982). The present study assesses the degree of recovery of GFR and effective renal plasma flow (ERPF) in a small group of patients with untreated MHT, who presented with normal or slightly raised serum creatinine concentration, and who were treated aggressively for hypertension from the time of admission.

Patients and methods
Four patients, emergency admissions to hospital on account of headaches (cases 1 and 2), and visual impairment (cases 3 and 4), were found to have untreated MHT with systolic blood pressure (SBP) of 220 mmHg or more, and diastolic blood pressure (DBP) of 140 mmHg or more. Hypertensive retinopathy (Grade IV—Keith-Wagener classification) was present in all patients. Anti-hypertensive drug treatment was commenced immediately, and good BP control was achieved within 1 week. Secondary hypertension was excluded by the following laboratory tests: (i) intravenous urography; (ii) gamma camera renography using technetium-99m DTPA; (iii) serum electrolyte concentrations; (iv) urinary catecholamine estimations; (v) microscopical analysis of urine deposit; and (vi) urine culture. Microangiopathic haemolytic anaemia was excluded by appropriate blood tests. Clinical examination and chest X-ray excluded cardiac failure. BP was measured by mercury sphygmomanometer, taking the fifth Korotkov sound as the end-point for DBP. After discharge from hospital the patient was reviewed at 2 or 3 month intervals.

During the first week of treatment GFR and ERPF were measured using 51Cr/EDTA and 125I/Hippuran, respectively, with a single-shot technique (Morgan et al., 1977). Sequential measurements were performed over a 5-year period.

Results
Clinical details, with mean levels of SBP and DBP before and at yearly intervals after commencing antihypertensive drug treatment, are given in Table 1.
TABLE 1. Mean SBP and DBP throughout 5 years of anti-hypertensive drug treatment

<table>
<thead>
<tr>
<th>Case</th>
<th>Sex/age</th>
<th>Pre-treatment (mmHg)</th>
<th>Post-treatment (mean) (mmHg)</th>
<th>Drug treatment regime</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F/35</td>
<td>SBP 228 DBP 158</td>
<td>134 128 130 110 110</td>
<td>Labetalol, 2400 mg/day</td>
</tr>
<tr>
<td>2</td>
<td>M/49</td>
<td>SBP 220 DBP 140</td>
<td>150 150 155 147-5 120</td>
<td>Metoprolol, 400 mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Prazosin, 0-5 mg tds</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Bendrofluazide, 5 mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Minoxidil, 10 mg bd</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(substituted for prazosin in year 3)</td>
</tr>
<tr>
<td>3</td>
<td>M/53</td>
<td>SBP 260 DBP 186</td>
<td>160 155 160 166-6 145</td>
<td>Methyldopa, 500 mg tds</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Labetalol, 400 mg tds</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>+200 mg nocte</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Bumetanide mane</td>
</tr>
<tr>
<td>4</td>
<td>F/62</td>
<td>SBP 290 DBP 190</td>
<td>163 148 140 140 150</td>
<td>Atenolol, 200 mg/day</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Apresoline, 75 mg/day</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hydrochlorothiazide</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>+ amiloride</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>In year 3 prazosin 1 mg bd was substituted for apresoline</td>
</tr>
</tbody>
</table>

Hypertensive retinopathy regressed and completely disappeared within 2 months of starting treatment.

Serial GFR and ERPF throughout 5 years of treatment are displayed in Figs. 1 and 2, respectively.

**Fig. 1.** GFR remained relatively constant during 5 years of adequate blood pressure control. Case: (○)1; (●)2; (□)3; (□)4.

**Discussion**

Serial GFR and ERPF determinations remained essentially unchanged throughout 5 years of effective anti-hypertensive drug treatment, presumably because of permanent structural damage to the renal vessels. In MHT these vascular changes may be related to (i) preceding vascular damage from chronic, severe, but benign hypertension (Reubl et al., 1978), or (ii) superimposed fibrinoid necrosis associated with MHT, which results from gross elevation of arterial BP or to accompanying humoral factors (Beilin and Goldby, 1977). Marked variation in the degree of initial reduction in GFR or ERPF in the present small series is consistent with a patchy distribution of fibrinoid necrosis within the arterioles. In cases 1 and 2 GFR was only mildly reduced, whereas in cases 3 and 4 there was more marked reduction.

The nature of these vascular changes, and their response to hypotensive therapy is open to speculation. The relatively constant GFR and ERPF, observed in all patients throughout treatment, contrasted with a gradual decline in SBP and DBP noted in each successive year of treatment, suggesting a poor relationship between these variables. It is
therefore difficult to define an optimal level of SBP or DBP at which GFR or ERPF will be stabilized or improved. For example, minoxidil improved BP control in case 2, when used in years 4 and 5, but this did not effect an improvement in ERPF which remained low. Probably the marked reduction in GFR and ERPF observed in cases 3 and 4 reflected widespread obliterator arteriolar disease, but the data cannot distinguish vascular changes accompanying benign hypertension from MHT.

A dramatic fall in serum creatinine concentration has been observed in some patients with MHT admitted with severe impairment of renal function, who were treated with the vasodilator minoxidil (Mitchell, Graham and Pettinger, 1980; McKay et al., 1981; Taverner et al., 1983). This suggests that in those patients it is possible to reverse the vascular component due to fibrinoid necrosis. Fibrinoid necrosis may cause several types of reno-vascular damage: Type 1 signifies a breach of endothelium permitting entry of plasma into the media; Type II results from internal deposition of fibrin and macrophages; and Type III represents a healing phase in which endothelial restoration is coordinated by smooth muscle cell repair action (Goldby and Beilin, 1974). The untreated patient with MHT may exhibit all three types. Careful pathological study of the renal vasculature in two patients with MHT, who died suddenly from acute cardiac failure before the development of renal failure, revealed widespread obliterator disease of the renal arterioles. Successive episodes of obliterator vascular disease had affected fresh groups of arterioles over a period of time, causing a variety of acute, healing and healed vascular lesions (Sanerkin, 1977). Hypertensive retinopathy, however, regressed completely over the first two months of treatment in the current series, indicating recovery of the retinal vessels during this time interval.

In conclusion, the present series of patients with MHT demonstrated little change in GFR and ERPF throughout adequate long-term control of BP. In cases 1 and 2 the initial reduction of GFR and ERPF was mild, and hypertensive drug treatment would not be expected to improve these variables to any great extent. Cases 3 and 4, with more severe reduction in GFR and ERPF may conceivably have had long-standing benign hypertension that could have produced persisting reno-vascular damage. But it is also possible that these patients could have had obliterator fibrinoid necrosis which did not respond to anti-hypertensive therapy. It should be recognized that not all patients with renal impairment due to MHT recover function following adequate treatment.

References
Beilin, L.J. & Goldby, F.S. (1977) High arterial pressure versus humoral factors in the pathogenesis of the vascular lesions of malignant hypertension. Clinical Science and Molecular Medicine, 52, 111.


(Accepted 17 April 1984)
Prospective measurement of glomerular filtration rate and effective renal plasma flow during treatment of malignant essential hypertension.

R. R. Ghose

Postgrad Med J 1984 60: 662-664
doi: 10.1136/pgmj.60.708.662

Updated information and services can be found at:
http://pmj.bmj.com/content/60/708/662

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/